Track topics on Twitter Track topics that are important to you
Horizon Discovery Group PLC (LON:HZD) has struck a subscription licensing deal with an unnamed partner, the first of its kind, for its bioproduction cell lines worth at least £500,000. The gene editing specialist said the partner will be given immediate access to Horizon's cutting-edge Null CHO K1 bioproduction cell line indefinitely for use in making new drugs. The CHO SOURCE platform delivers a fully engineered and characterised host cell line, ideally suited to the manufacture of recombinant protein therapeutics. The commercial group will also be able to access Horizon's programme of continuous cell line innovation, enabling them to license, via the subscription, any follow-on cell lines developed as part of the program at a 50% discount within five years. The minimum fee will be paid up front, with a significant amount to be recognised in full year 2016, Horizon said. Horizon's chief executive Dr Darrin Disley told investors: "Horizon continues to be a disruptive influence in the bioproduction arena, using technical and commercial innovation to accelerate advancements in drug manufacturing. "This new announcement further validates our approach, with our partner demonstrating their confidence by making a five year commitment via subscription model to the program. We look forward to making further announcements in this area as Horizon continues its momentum as a key player in the bioproduction space." Today's deal follows a lengthy evaluation period started in the fourth quarter of 2015 and underlines the confidence in the partner that Horizon will provide a number of additional cell lines over the next five years, leading to significant efficiency improvements in their biomanufacturing capability.
Original Article: Horizon Discovery strikes new licensing deal for bioproduction linesNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...